Evidence map›Paper›PMID 34147358›Full record

ArticleTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2021

COVID-19 antibody donation using immunoadsorption: Report of two cases.

Jannik Rothenburg, Silke Rink-Baron, Lisa Mueller, Philipp Niklas Ostermann, Johannes Fischer, Johannes Stegbauer, Anja Moldenhauer

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Immunoadsorption and covid 19 pandemic.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jannik RothenburgInstitute for Transplantat Diagnostics and Cell Therapeutics, University Hospital Düsseldorf, Heinrich-Heine-University, Germany; Pall Corporation, Dreieich, Germany.
Silke Rink-BaronMiltenyi Biotec, Bergisch Gladbach, Germany.
Lisa MuellerInstitute of Virology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Germany.
Philipp Niklas OstermannInstitute of Virology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Germany.
Johannes FischerInstitute for Transplantat Diagnostics and Cell Therapeutics, University Hospital Düsseldorf, Heinrich-Heine-University, Germany.
Johannes StegbauerDepartment of Nephrology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, Germany.
Anja MoldenhauerInstitute for Transplantat Diagnostics and Cell Therapeutics, University Hospital Düsseldorf, Heinrich-Heine-University, Germany; Saarland University, Homburg, Germany. Electronic address: moldenha@hhu.de.
Düsseldorf University Hospital · DEMiltenyi Biotec (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For more than a year the whole world is suffering from the COVID-19 pandemic with no treatment option in sight. Administration of plasma from convalescent donors containing anti-SARS-CoV-2 antibodies, though promising according to case reports, failed to show a clear benefit in a greater number of trials. One reason could be varying and low antibody contents in a majority of plasma units hampering standardization and clinical efficacy. Besides, other plasma components unnecessarily transfused like coagulation factors might promote hypercoagulation seen in severe COVID-19 etiopathology. We therefore hypothesized that instead of collecting whole plasma units, convalescent donors could donate solely immunoglobulins by undergoing immunoadsorption, a mode of therapy regularly applied in autoimmune diseases. Here, we report the results of the first two antibody donations performed at the University Hospital Düsseldorf. In both cases, immunoadsorptions were very well tolerated with no side effects. Collected and neutralized eluates were concentrated using tangential flow filtration increasing the concentration of immunoglobulins 10fold as compared to peripheral blood and leading to probably eight times more neutralizing antibodies than in one plasma unit. Therefore, immunoadsorption can be used as a method of antibody donation. Whether these donated antibodies can be used as passive immunization in acutely infected patients remains to be elucidated.

Indexed as

Immunosorbent TechniquesAntibodies, NeutralizingAntibodies, ViralConvalescenceCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralAntibody donationCOVID-19 convalescenceImmunoadsorptionVirus neutralization

Identifiers

PMID34147358
PMCPMC8205282
OpenAlexW3169801524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.